Pα+ Psychedelic Patent Analysis: March 2024 – Psychedelic Alpha

General Overview
First Look at Nolan Williams et al.’s Ibogaine IP: Is Co-Administration of Magnesium and Ibogaine Common Practice?
Clexio Biosciences Protects CLE-100 Development Programs
Broad Strokes Attempt from Axsome Fails to Overcome Prior Art
NYU Abandons “Hot Psilocybin Patent Garbage”

***

Each month, we provide an interactive database of psychedelic patents that were granted, allowed, abandoned, rejected or that had responses filed.

We then provide detail and analysis on a handful of specific cases, or one deep dive.

Our monthly Psychedelic Patent Analysis is exclusively for Pα+ subscribers. Head to our Join page to learn more, or sign in to your account.

Companies, organisations and candidates mentioned in this analysis: DemeRx, Axsome Therapeutics, Empyrean Neuroscience, Tactogen, Clexio Biosciences, CLE-100, Gilgamesh Pharmaceuticals, MindMed, Awakn Life Sciences, and others.

Bipolar disorder cuts lives short more than smoking

Having bipolar disorder – a serious mental illness that can cause both manic and depressed moods – can make life more challenging.

January 5, 2024

Current and future strategies for vaccinating against invasive pneumococcal disease

Researchers reviewed the immune mechanisms employed by existing vaccines for invasive pneumococcal disease.

August 23, 2023

Medical Cannabis-Arrhythmia Link; Watch Out for Lipoprotein(a); New SAVR Alternative

Medical marijuana was associated with an elevated risk of new-onset arrhythmia in a Danish population with chronic pain. (European Heart Journal) Severe drug-induced QT prolongation

January 17, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.